Dimeric high affinity EGFR constructs and uses thereof
    2.
    发明授权
    Dimeric high affinity EGFR constructs and uses thereof 有权
    二聚高亲和力EGFR构建体及其用途

    公开(公告)号:US08278415B2

    公开(公告)日:2012-10-02

    申请号:US12514631

    申请日:2007-12-20

    IPC分类号: C07K14/00

    摘要: Polypeptides comprising EGFR extracellular domains I-III capable of forming dimeric EGF-binding proteins are provided. The dimeric construct of the invention is useful in applications where high affinity EGF binding is desired and can be used to select agents capable of binding to native EGFR in the presence of EGF.

    摘要翻译: 提供了包含能够形成二聚体EGF结合蛋白的EGFR细胞外结构域I-III的多肽。 本发明的二聚体构建体可用于需要高亲和力EGF结合并可用于选择能在EGF存在下与天然EGFR结合的试剂的应用中。

    Epitope directed selection of antibodies to murine tissue factor
    5.
    发明授权
    Epitope directed selection of antibodies to murine tissue factor 有权
    表位定向选择抗小鼠组织因子的抗体

    公开(公告)号:US07514539B2

    公开(公告)日:2009-04-07

    申请号:US11112481

    申请日:2005-04-22

    IPC分类号: C07K16/00

    摘要: A tissue factor antibody which binds to non-human tissue factor and is useful as a surrogate in preclinical testing where the human therapeutic tissue factor candidate antibody does not interact with the homolog target protein in a manner that would provide meaningful information about treatment efficacy or safety.

    摘要翻译: 结合非人组织因子的组织因子抗体并且可用作临床前测试中的替代物,其中人治疗组织因子候选抗体不以与提供关于治疗功效或安全性的有意义的信息的方式与同源物靶蛋白相互作用 。

    IL-23p40 specific antibody
    9.
    发明授权
    IL-23p40 specific antibody 有权
    IL-23p40特异性抗体

    公开(公告)号:US07247711B2

    公开(公告)日:2007-07-24

    申请号:US10840789

    申请日:2004-05-06

    摘要: Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived proteins, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, are useful for therapeutic compositions, methods and devices. Preferably, the anti-IL-23p40 specific human Ig derived proteins do not bind the p40 subunit of IL-12 and, thus, do not neutralize IL-12-related activity.

    摘要翻译: 新型抗IL-23p40特异性人Ig衍生蛋白,包括但不限于抗体,融合蛋白和模拟抗体,编码抗IL-23p40Ig衍生蛋白质的分离的核酸,载体,宿主细胞,转基因动物或植物, 及其制备和使用方法可用于治疗组合物,方法和装置。 优选地,抗IL-23p40特异性人Ig衍生的蛋白质不结合IL-12的p40亚基,因此不中和IL-12相关活性。